Pharmacologic modulation of autonomic tone: implications for the diabetic patient.
Aronson
D
D
Research Division, Joslin Diabetes Center, Boston, Massachusetts 02215, USA.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001341:Autonomic Nervous System / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology*; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000209:etiology / Q000503:physiopathology; D016757:Death, Sudden, Cardiac / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000503:physiopathology*; D003925:Diabetic Angiopathies / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000401:mortality / Q000503:physiopathology*; D004198:Disease Susceptibility; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D014693:Ventricular Fibrillation / Q000453:epidemiology / Q000209:etiology
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents